Pritelivir is a first in class thiazolylamide under investigation for treatment of herpes simplex virus. It is thought to act by preventing de novo synthesis of virus DNA through inhibition of the helicase-primase complex. The authors of this study acknowledge that further research is needed to assess longer-term efficacy and safety.